WO2004058184A3 - Anti-ngf antibodies and methods using same - Google Patents
Anti-ngf antibodies and methods using same Download PDFInfo
- Publication number
- WO2004058184A3 WO2004058184A3 PCT/US2003/041252 US0341252W WO2004058184A3 WO 2004058184 A3 WO2004058184 A3 WO 2004058184A3 US 0341252 W US0341252 W US 0341252W WO 2004058184 A3 WO2004058184 A3 WO 2004058184A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- same
- pain
- antibodies
- methods
- ngf antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Priority Applications (25)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT03800170T ATE553128T1 (en) | 2002-12-24 | 2003-12-24 | ANTI-NGF ANTIBODIES AND METHOD OF USE THEREOF |
KR1020127025397A KR101410692B1 (en) | 2002-12-24 | 2003-12-24 | Anti-ngf antibodies and methods using same |
SI200332143T SI1575517T1 (en) | 2002-12-24 | 2003-12-24 | Anti-ngf antibodies and methods using same |
EP18195127.8A EP3539569A1 (en) | 2002-12-24 | 2003-12-24 | Anti-ngf antibodies and methods using the same in treating pain associated with musculo-skeletal disorders |
EA200501043A EA011479B1 (en) | 2002-12-24 | 2003-12-24 | Anti-ngf antibodies and methods using same |
ES03800170T ES2382918T3 (en) | 2002-12-24 | 2003-12-24 | Anti-NGF antibodies and procedures using them |
NZ540730A NZ540730A (en) | 2002-12-24 | 2003-12-24 | Anti-NGF antibodies and methods using same |
CA2511598A CA2511598C (en) | 2002-12-24 | 2003-12-24 | Anti-ngf antibodies and methods using same |
JP2005510064A JP4134170B2 (en) | 2002-12-24 | 2003-12-24 | Anti-NGF antibodies and methods of using them |
KR1020057011944A KR101250818B1 (en) | 2002-12-24 | 2003-12-24 | Anti-ngf antibodies and methods using same |
MXPA05006854A MXPA05006854A (en) | 2002-12-24 | 2003-12-24 | Anti-ngf antibodies and methods using same. |
CN2003801099334A CN101014364B (en) | 2002-12-24 | 2003-12-24 | Anti-ngf antibodies and methods using same |
BRPI0317738A BRPI0317738B8 (en) | 2002-12-24 | 2003-12-24 | anti-ngf antibodies or fragments thereof, their method of manufacture, use, polynucleotide, vector and transgenic microorganism, as well as pharmaceutical composition and kit comprising said antibodies or fragments |
EP03800170A EP1575517B1 (en) | 2002-12-24 | 2003-12-24 | Anti-ngf antibodies and methods using same |
EP10176615.2A EP2263692B1 (en) | 2002-12-24 | 2003-12-24 | Anti-NGF antibodies and methods using same |
AU2003299898A AU2003299898B2 (en) | 2002-12-24 | 2003-12-24 | Anti-NGF antibodies and methods using same |
DK03800170.7T DK1575517T3 (en) | 2002-12-24 | 2003-12-24 | ANTI-NGF ANTIBODIES AND PROCEDURES FOR USING THE SAME |
IL169221A IL169221A (en) | 2002-12-24 | 2005-06-16 | Anti-ngf antibodies, pharmaceutical compositions comprising same and use thereof in the manufacture of medicaments for the treatment of pain |
NO20053583A NO336655B1 (en) | 2002-12-24 | 2005-07-22 | Anti-nerve growth factor (NGF) antibody, or fragment thereof, pharmaceutical composition and the like thereof, methods of their preparation, isolated polynucleotide, vector and isolated host cell and use thereof for the treatment of pain, especially pain associated with osteoarthritis. |
HK05110620.2A HK1076251A1 (en) | 2002-12-24 | 2005-11-23 | Anti-ngf antibodies and methods using same |
HK08101386.2A HK1110513A1 (en) | 2002-12-24 | 2008-02-05 | Anti-ngf antibodies and methods using same |
AU2011201157A AU2011201157C1 (en) | 2002-12-24 | 2011-03-16 | Anti-NGF antibodies and methods using same |
IL218087A IL218087B (en) | 2002-12-24 | 2012-02-13 | Anti-ngf antibodies and methods using the same |
NO20150469A NO339595B1 (en) | 2002-12-24 | 2015-04-20 | Anti-nerve growth factor (NGF) antagonist antibody or antigen binding fragment thereof for use in the treatment of osteoarthritis pain in an individual and for use in the manufacture of a medicament for the treatment of osteoarthritis pain in an individual. |
IL263573A IL263573A (en) | 2002-12-24 | 2018-12-09 | Anti-ngf antibodies and methods using same |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43690502P | 2002-12-24 | 2002-12-24 | |
US60/436,905 | 2002-12-24 | ||
US44352203P | 2003-01-28 | 2003-01-28 | |
US60/443,522 | 2003-01-28 | ||
US51000603P | 2003-10-08 | 2003-10-08 | |
US60/510,006 | 2003-10-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004058184A2 WO2004058184A2 (en) | 2004-07-15 |
WO2004058184A3 true WO2004058184A3 (en) | 2006-07-27 |
Family
ID=32686099
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/041252 WO2004058184A2 (en) | 2002-12-24 | 2003-12-24 | Anti-ngf antibodies and methods using same |
Country Status (23)
Country | Link |
---|---|
US (6) | US7449616B2 (en) |
EP (4) | EP3539569A1 (en) |
JP (3) | JP4134170B2 (en) |
KR (2) | KR101250818B1 (en) |
CN (2) | CN102746399B (en) |
AT (1) | ATE553128T1 (en) |
AU (1) | AU2003299898B2 (en) |
BR (1) | BRPI0317738B8 (en) |
CA (3) | CA2511598C (en) |
DK (3) | DK1575517T3 (en) |
EA (1) | EA011479B1 (en) |
ES (3) | ES2697876T3 (en) |
HK (3) | HK1076251A1 (en) |
HU (1) | HUE026089T2 (en) |
IL (3) | IL169221A (en) |
MX (1) | MXPA05006854A (en) |
NO (2) | NO336655B1 (en) |
NZ (2) | NZ540730A (en) |
PL (1) | PL215171B1 (en) |
PT (3) | PT2263692T (en) |
SI (3) | SI1575517T1 (en) |
WO (1) | WO2004058184A2 (en) |
ZA (1) | ZA200504866B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8030469B2 (en) | 2005-07-22 | 2011-10-04 | Sbi Incubation Co., Ltd. | Anti-CD26 antibodies and methods of use thereof |
US8435523B2 (en) | 2009-05-04 | 2013-05-07 | Abbott Research B.V. | Antibodies against nerve growth factor (NGF) with enhanced in vivo stability |
US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
Families Citing this family (167)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060147450A1 (en) * | 2002-10-04 | 2006-07-06 | Shelton David L | Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists |
AU2003304238A1 (en) * | 2002-10-08 | 2005-01-13 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same |
RU2338555C2 (en) * | 2002-10-08 | 2008-11-20 | Ринат Ньюросайенс Корп. | Method of treatment of postoperative pain by administering of antagonist of factor of growth of nerves and compositions containing factor of growth of nerves |
UA80447C2 (en) * | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
US7569364B2 (en) * | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
SI1575517T1 (en) * | 2002-12-24 | 2012-06-29 | Rinat Neuroscience Corp | Anti-ngf antibodies and methods using same |
US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
PL379983A1 (en) | 2003-02-19 | 2006-11-27 | Rinat Neuroscience Corp. | Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same |
NZ544751A (en) * | 2003-07-15 | 2009-05-31 | Amgen Inc | Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors |
KR20070001932A (en) | 2003-12-23 | 2007-01-04 | 리나트 뉴로사이언스 코퍼레이션 | Agonist anti-trkc antibodies and methods using same |
ITRM20030601A1 (en) * | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | METHOD FOR THE HUMANIZATION OF HUMANIZED ANTIBODIES AND ANTIBODIES WITH IT OBTAINED. |
JP5301152B2 (en) * | 2004-04-07 | 2013-09-25 | ライナット ニューロサイエンス コーポレイション | Method for treating bone cancer pain by administering a nerve growth factor antagonist |
ME00226B (en) | 2004-07-15 | 2011-02-10 | Medarex Llc | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors |
TWI355389B (en) | 2004-07-30 | 2012-01-01 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide a |
CA2595800C (en) | 2005-01-24 | 2014-07-08 | Cambridge Antibody Technology Limited. | Specific binding members for ngf |
US10011858B2 (en) | 2005-03-31 | 2018-07-03 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
UY29504A1 (en) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | DIRECTED ANTIBODIES AGAINST BETA AMYLOID PEPTIDE AND METHODS USING THE SAME. |
ITRM20050290A1 (en) * | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | USE OF MOLECULES ABLE TO INHIBIT THE BOND BETWEEN NGF AND ITS TRKA RECEPTOR AS AN EXTENDED EFFECT ANALGESICS. |
CA2862540C (en) | 2005-09-21 | 2018-07-31 | The Regents Of The University Of California | Systems, compositions, and methods for local imaging and treatment of pain |
DK3045182T3 (en) | 2005-11-14 | 2018-03-19 | Teva Pharmaceuticals Int Gmbh | ANTAGONIST ANTIBODIES AGAINST CALCITONIN GEN-RELATED PEPTIDE TO TREAT HEAT |
EP3345616A1 (en) | 2006-03-31 | 2018-07-11 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
US20100166734A1 (en) * | 2006-12-20 | 2010-07-01 | Edward Dolk | Oral delivery of polypeptides |
AU2008218925A1 (en) | 2007-02-20 | 2008-08-28 | Anaptysbio, Inc. | Somatic hypermutation systems |
AU2012216653B2 (en) * | 2007-08-10 | 2013-12-12 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human nerve growth factor |
US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
KR101709488B1 (en) | 2007-08-10 | 2017-02-24 | 리제너론 파아마슈티컬스, 인크. | High affinity human antibodies to human nerve growth factor |
WO2009032949A2 (en) * | 2007-09-04 | 2009-03-12 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection |
EP3415529B1 (en) * | 2007-09-26 | 2020-11-04 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant region |
US9096651B2 (en) | 2007-09-26 | 2015-08-04 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
JP5737944B2 (en) * | 2007-12-17 | 2015-06-17 | ファイザー・リミテッドPfizer Limited | Treatment of interstitial cystitis |
EP2282769A4 (en) | 2008-04-29 | 2012-04-25 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
CA2725666A1 (en) | 2008-06-03 | 2009-12-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
RU2010153580A (en) | 2008-06-03 | 2012-07-20 | Эбботт Лэборетриз (Us) | IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND THEIR APPLICATION |
WO2009150623A1 (en) | 2008-06-13 | 2009-12-17 | Pfizer Inc | Treatment of chronic prostatitis |
JP5674654B2 (en) | 2008-07-08 | 2015-02-25 | アッヴィ・インコーポレイテッド | Prostaglandin E2 double variable domain immunoglobulin and use thereof |
WO2010029497A1 (en) * | 2008-09-12 | 2010-03-18 | Pfizer Limited | Treatment of endometriosis |
TWI516501B (en) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Pcsk9 antagonists |
EP2166358A1 (en) * | 2008-09-17 | 2010-03-24 | Fundacio Institut de Recerca de l'Hospital Universitari Vall d'Hebron | Differential diagnostic biomarkers of stroke mimicking conditions and methods of use thereof |
BRPI0917888A2 (en) * | 2008-09-19 | 2014-02-25 | Pfizer | STABLE NET ANTIBODY FORMULATION |
TWI440469B (en) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
CN102292338B (en) * | 2008-12-08 | 2016-09-28 | 萌蒂制药国际有限公司 | Compositions of protein receptor tyrosine kinase inhibitors |
WO2010086828A2 (en) | 2009-02-02 | 2010-08-05 | Rinat Neuroscience Corporation | Agonist anti-trkb monoclonal antibodies |
US20100256524A1 (en) | 2009-03-02 | 2010-10-07 | Seventh Sense Biosystems, Inc. | Techniques and devices associated with blood sampling |
US9041541B2 (en) | 2010-01-28 | 2015-05-26 | Seventh Sense Biosystems, Inc. | Monitoring or feedback systems and methods |
US9033898B2 (en) * | 2010-06-23 | 2015-05-19 | Seventh Sense Biosystems, Inc. | Sampling devices and methods involving relatively little pain |
WO2010146511A1 (en) | 2009-06-17 | 2010-12-23 | Pfizer Limited | Treatment of overactive bladder |
US9090690B2 (en) | 2009-06-18 | 2015-07-28 | Pfizer Inc. | Anti Notch-1 antibodies |
TW201119673A (en) | 2009-09-01 | 2011-06-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
TW201119676A (en) * | 2009-10-15 | 2011-06-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
UY32979A (en) | 2009-10-28 | 2011-02-28 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
EP2493537B1 (en) * | 2009-10-30 | 2017-12-06 | Seventh Sense Biosystems, Inc. | Systems and methods for treating, sanitizing, and/or shielding the skin or devices applied to the skin |
US8298535B2 (en) | 2010-02-24 | 2012-10-30 | Rinat Neuroscience Corp. | Anti-IL-7 receptor antibodies |
SI2542257T1 (en) | 2010-03-01 | 2018-01-31 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
PE20130393A1 (en) | 2010-03-11 | 2013-04-07 | Rinat Neuroscience Corp | ANTIBODIES WITH PH-DEPENDENT ANTIGEN UNION |
US20110256135A1 (en) | 2010-03-17 | 2011-10-20 | Wolfgang Fraunhofer | Anti-nerve growth factor (ngf) antibody compositions |
ES2561824T3 (en) | 2010-07-16 | 2016-03-01 | Seventh Sense Biosystems, Inc. | Low pressure environment for fluid transfer devices |
US20130158482A1 (en) | 2010-07-26 | 2013-06-20 | Seventh Sense Biosystems, Inc. | Rapid delivery and/or receiving of fluids |
CA2807014A1 (en) | 2010-08-03 | 2012-02-09 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
WO2012021801A2 (en) | 2010-08-13 | 2012-02-16 | Seventh Sense Biosystems, Inc. | Systems and techniques for monitoring subjects |
US9505829B2 (en) * | 2010-08-19 | 2016-11-29 | Zoetis Belgium S.A. | Anti-NGF antibodies and their use |
AU2015258217A1 (en) * | 2010-08-19 | 2015-12-03 | Zoetis Belgium S.A. | Anti-NGF antibodies and their use |
CA2809433A1 (en) | 2010-08-26 | 2012-03-01 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
WO2012064802A1 (en) | 2010-11-09 | 2012-05-18 | Seventh Sense Biosystems, Inc. | Systems and interfaces for blood sampling |
US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
US9783601B2 (en) * | 2010-12-01 | 2017-10-10 | Alderbio Holdings Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
CA2821130C (en) | 2010-12-15 | 2017-11-07 | Wyeth Llc | Anti-notch1 antibodies |
EP2665750A1 (en) * | 2011-01-17 | 2013-11-27 | Novo Nordisk A/S | Il-21 ligands |
KR102237667B1 (en) | 2011-04-29 | 2021-04-12 | 세븐쓰 센스 바이오시스템즈, 인크. | Delivering and/or receiving fluids |
EP2702406B1 (en) | 2011-04-29 | 2017-06-21 | Seventh Sense Biosystems, Inc. | Plasma or serum production and removal of fluids under reduced pressure |
US20130158468A1 (en) | 2011-12-19 | 2013-06-20 | Seventh Sense Biosystems, Inc. | Delivering and/or receiving material with respect to a subject surface |
EP2701598A1 (en) | 2011-04-29 | 2014-03-05 | Seventh Sense Biosystems, Inc. | Systems and methods for collecting fluid from a subject |
EA033109B1 (en) | 2011-05-20 | 2019-08-30 | Олдербайо Холдингз Ллк | Methods of inhibiting, preventing or treating diarrhea and/or maintaining appropriate electrolyty and fluid levels in the colon of a subject having a condition associated with diarrhea using an anti-cgrp antibody or an anti-cgrp antibody fragment |
JP6374789B2 (en) | 2011-05-20 | 2018-08-15 | アルダーバイオ・ホールディングズ・エルエルシー | Use of anti-CGRP antibodies and antibody fragments that prevent or inhibit photophobia or photoaversion in subjects in need thereof, particularly migraine patients |
SG10201604040PA (en) | 2011-05-20 | 2016-07-28 | Alderbio Holdings Llc | Anti-cgrp compositions and use thereof |
WO2013009582A1 (en) | 2011-07-12 | 2013-01-17 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
US8986952B2 (en) | 2011-08-11 | 2015-03-24 | Astellas Pharma Inc. | Anti-human NGF antibody |
SG11201401699WA (en) | 2011-11-11 | 2014-09-26 | Rinat Neuroscience Corp | Antibodies specific for trop-2 and their uses |
EP2794659A1 (en) | 2011-12-22 | 2014-10-29 | Rinat Neuroscience Corp. | Human growth hormone receptor antagonist antibodies and methods of use thereof |
WO2013093693A1 (en) | 2011-12-22 | 2013-06-27 | Rinat Neuroscience Corp. | Staphylococcus aureus specific antibodies and uses thereof |
BR112014015851A2 (en) | 2011-12-30 | 2019-09-24 | Abbvie Inc | double specific binding proteins directed against il-13 and / or il-17 |
US9386657B2 (en) | 2012-03-15 | 2016-07-05 | Universal Display Corporation | Organic Electroluminescent materials and devices |
JP6629069B2 (en) | 2012-06-06 | 2020-01-15 | ゾエティス・エルエルシー | Canine anti-NGF antibody and method thereof |
SG11201503412RA (en) | 2012-11-01 | 2015-05-28 | Abbvie Inc | Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof |
AU2013343099A1 (en) | 2012-11-09 | 2015-05-14 | Pfizer Inc. | Platelet-derived growth factor B specific antibodies and compositions and uses thereof |
US9127055B2 (en) | 2013-02-08 | 2015-09-08 | Astellas Pharma Inc. | Method of treating pain with anti-human NGF antibody |
CN105324396A (en) | 2013-03-15 | 2016-02-10 | 艾伯维公司 | Dual specific binding proteins directed against il-1 beta and il-17 |
RU2015147721A (en) | 2013-05-07 | 2017-06-15 | Ринат Нейросаенз Корпорэйшн | ANTIBODIES AGAINST GLUCAGON RECEPTOR AND METHODS OF USING THEM |
AR097102A1 (en) | 2013-08-02 | 2016-02-17 | Pfizer | ANTI-CXCR4 ANTIBODY AND ANTIBODY AND DRUG CONJUGATES |
PT3050896T (en) | 2013-09-27 | 2021-08-24 | Chugai Pharmaceutical Co Ltd | Method for producing polypeptide heteromultimer |
WO2015073580A1 (en) | 2013-11-13 | 2015-05-21 | Pfizer Inc. | Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof |
WO2015087187A1 (en) | 2013-12-10 | 2015-06-18 | Rinat Neuroscience Corp. | Anti-sclerostin antibodies |
WO2015109212A1 (en) | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anti-il-2 antibodies and compositions and uses thereof |
RU2659068C1 (en) | 2014-02-05 | 2018-06-28 | Вм Онколоджи Ллк | Composition of compounds and ways of their application |
PE20161439A1 (en) | 2014-03-21 | 2017-01-26 | Teva Pharmaceuticals Int Gmbh | ANTIBODIES ANTAGONISTS DIRECTED AGAINST THE PEPTIDE RELATED TO THE CALCITONIN GENE AND METHODS USING THE SAME |
WO2015143654A1 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
WO2015143652A1 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
WO2015143653A1 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
TWI595006B (en) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | Anti-pd-1 antibodies and methods of use thereof |
WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
CA2972393A1 (en) | 2015-02-27 | 2016-09-01 | Chugai Seiyaku Kabushiki Kaisha | Composition for treating il-6-related diseases |
EP3279216A4 (en) | 2015-04-01 | 2019-06-19 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide hetero-oligomer |
WO2016161572A1 (en) | 2015-04-08 | 2016-10-13 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
TWI787645B (en) | 2015-04-13 | 2022-12-21 | 美商輝瑞股份有限公司 | Cd3-specific antibodies, therapeutic bispecific antibodies and their uses |
US10647756B2 (en) | 2015-05-18 | 2020-05-12 | Pfizer Inc. | Humanized antibodies |
CA2986210C (en) | 2015-05-22 | 2022-04-26 | Astellas Pharma Inc. | Novel anti-human ngf antibody fab fragment |
TW201710286A (en) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | Binding proteins against VEGF, PDGF, and/or their receptors |
WO2017015619A1 (en) | 2015-07-23 | 2017-01-26 | The Regents Of The University Of California | Antibodies to coagulation factor xia and uses thereof |
IL302353A (en) | 2015-08-19 | 2023-06-01 | Pfizer | Tissue factor pathway inhibitor antibodies and uses thereof |
SG10202107733QA (en) | 2015-09-28 | 2021-09-29 | Univ North Carolina Chapel Hill | Methods and compositions for antibody-evading virus vectors |
US10138298B2 (en) | 2015-10-23 | 2018-11-27 | The Regents Of The University Of California | Anti-IL-2 antibodies and compositions and uses thereof |
EP3398965A4 (en) | 2015-12-28 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of fc region-containing polypeptide |
ES2904593T3 (en) | 2016-01-21 | 2022-04-05 | Pfizer | Monospecific and bispecific antibodies to epidermal growth factor receptor variant III and CD3 and their uses |
PE20181952A1 (en) | 2016-04-27 | 2018-12-17 | Pfizer | ANTI-LL-33 ANTIBODIES, COMPOSITIONS, METHODS AND USES OF THE SAME |
EP3448419B1 (en) | 2016-04-29 | 2023-06-07 | Pfizer Inc. | Interferon beta antibodies and uses thereof |
EP3468587A4 (en) | 2016-06-09 | 2020-02-19 | University of Leicester | Monoclonal antibodies, compositions and methods for detecting mucin -like protein (mlp) as a biomarker for ovarian and pancreatic cancer |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
AU2017331593B2 (en) | 2016-09-23 | 2022-04-28 | Teva Pharmaceuticals International Gmbh | Treating refractory migraine |
AU2017331592A1 (en) | 2016-09-23 | 2019-04-11 | Teva Pharmaceuticals International Gmbh | Treating cluster headache |
WO2018088850A2 (en) * | 2016-11-11 | 2018-05-17 | 다이노나(주) | Antibody binding specifically to cd40 and use thereof |
MA46951A (en) | 2016-11-29 | 2019-10-09 | Regeneron Pharma | PHARMACEUTICAL COMPOSITION INTENDED TO PREVENT OPIOID DEPENDENCE |
US11198735B2 (en) | 2017-03-03 | 2021-12-14 | Rinat Neuroscience Corp. | Anti-GITR antibodies and methods of use thereof |
JP2020512825A (en) | 2017-04-12 | 2020-04-30 | ファイザー・インク | Antibodies with conditional affinity and methods of use thereof |
US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
CA3006798A1 (en) | 2017-06-02 | 2018-12-02 | Pfizer Inc. | Antibodies specific for flt3 and their uses |
AU2018279705A1 (en) | 2017-06-09 | 2019-11-14 | Boston Medical Center Corporation | Anti-ROBO2 antibodies, compositions, methods and uses thereof |
US20190048073A1 (en) | 2017-07-20 | 2019-02-14 | Pfizer Inc. | Anti-gd3 antibodies and antibody-drug conjugates |
MX2020005662A (en) | 2017-12-01 | 2020-08-20 | Pfizer | Anti-cxcr5 antibodies and compositions and uses thereof. |
CN108059676B (en) * | 2017-12-28 | 2020-07-31 | 未名生物医药有限公司 | Anti-human nerve growth factor scFv antibody and preparation method thereof |
AU2019215075A1 (en) | 2018-02-01 | 2020-08-20 | Pfizer Inc. | Antibodies specific for CD70 and their uses |
SG11202006883QA (en) | 2018-02-01 | 2020-08-28 | Pfizer | Chimeric antigen receptors targeting cd70 |
AR114110A1 (en) | 2018-02-28 | 2020-07-22 | Lilly Co Eli | ANTI-TRKA ANTIBODY |
WO2019177690A1 (en) | 2018-03-12 | 2019-09-19 | Zoetis Services Llc | Anti-ngf antibodies and methods thereof |
CN112119090B (en) | 2018-03-15 | 2023-01-13 | 中外制药株式会社 | Anti-dengue virus antibodies cross-reactive to Zika virus and methods of use |
CN108623687A (en) * | 2018-04-17 | 2018-10-09 | 中山康方生物医药有限公司 | The monoclonal antibody and its encoding gene of nerve growth factor and application |
US20210147529A1 (en) | 2018-05-15 | 2021-05-20 | Astellas Pharma Inc. | Pharmaceutical composition for suppressing atrial fibrillation having as active ingredient anti-human ngf antibody or antigen-binding fragment thereof |
EP3797121A1 (en) | 2018-05-23 | 2021-03-31 | Pfizer Inc | Antibodies specific for cd3 and uses thereof |
CA3100829A1 (en) | 2018-05-23 | 2019-11-28 | Pfizer Inc. | Antibodies specific for gucy2c and uses thereof |
JP7460598B2 (en) | 2018-08-10 | 2024-04-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Pharmaceutical Composition for the Safe and Effective Treatment of Knee and/or Hip Pain - Patent application |
MX2021001841A (en) | 2018-08-20 | 2021-05-13 | Pfizer | Anti-gdf15 antibodies, compositions and methods of use. |
JP2022508015A (en) | 2018-09-07 | 2022-01-19 | ファイザー・インク | Anti-αvβ8 antibody, composition and use thereof |
MX2021008267A (en) | 2019-01-08 | 2021-08-05 | H Lundbeck As | Acute treatment and rapid treatment of headache using anti-cgrp antibodies. |
JP2020117502A (en) | 2019-01-28 | 2020-08-06 | ファイザー・インク | Method of treating signs and symptoms of osteoarthritis |
AU2020216295A1 (en) | 2019-01-28 | 2021-09-09 | Maple Biotech Llc | PSMP antagonists for use in treatment of fibrotic disease of the lung, kidney or liver |
JP2020143045A (en) | 2019-02-18 | 2020-09-10 | ファイザー・インク | Method of treatment of chronic low back pain |
CN113924315B (en) * | 2019-06-10 | 2022-06-28 | 山东博安生物技术股份有限公司 | anti-beta-NGF nano antibody and application thereof |
US20220314142A1 (en) | 2019-07-01 | 2022-10-06 | Pfizer Inc. | Improvements to wash solutions for protein a chromatography in an antibody purification process |
EP4045641A1 (en) | 2019-10-15 | 2022-08-24 | Eli Lilly and Company | Recombinantly engineered, lipase/esterase-deficient mammalian cell lines |
AU2020367532A1 (en) | 2019-10-17 | 2022-05-12 | Ginkgo Bioworks, Inc. | Adeno-associated viral vectors for treatment of Niemann-Pick disease type C |
WO2021124267A1 (en) | 2019-12-20 | 2021-06-24 | Pfizer Inc. | Endotoxin detection |
CN113045655A (en) | 2019-12-27 | 2021-06-29 | 高诚生物医药(香港)有限公司 | anti-OX 40 antibodies and uses thereof |
WO2021205325A1 (en) | 2020-04-08 | 2021-10-14 | Pfizer Inc. | Anti-gucy2c antibodies and uses thereof |
CN113527482B (en) | 2020-04-17 | 2023-07-21 | 珠海泰诺麦博制药股份有限公司 | Antibodies against human nerve growth factor |
US20230220057A1 (en) | 2020-05-27 | 2023-07-13 | Staidson (Beijing) Biopharmaceuticals Co., Ltd. | Antibodies specifically recognizing nerve growth factor and uses thereof |
JP2023533793A (en) | 2020-07-17 | 2023-08-04 | ファイザー・インク | Therapeutic antibodies and their uses |
WO2022178090A2 (en) | 2021-02-19 | 2022-08-25 | Theripion, Inc. | Dnase fusion polypeptides and related compositions and methods |
WO2022195504A1 (en) | 2021-03-19 | 2022-09-22 | Pfizer Inc. | Method of treating osteoarthritis pain with an anti ngf antibody |
KR20240006586A (en) | 2021-05-12 | 2024-01-15 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Antigen-binding molecules that specifically bind to RANKL and NGF, and medical uses thereof |
WO2023007374A1 (en) | 2021-07-27 | 2023-02-02 | Pfizer Inc. | Method of treatment of cancer pain with tanezumab |
WO2023079430A1 (en) | 2021-11-02 | 2023-05-11 | Pfizer Inc. | Methods of treating mitochondrial myopathies using anti-gdf15 antibodies |
WO2023092052A1 (en) | 2021-11-19 | 2023-05-25 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for reducing centralized pain |
WO2023097275A1 (en) * | 2021-11-23 | 2023-06-01 | Invetx, Inc. | Anti-ngf antibodies and uses thereof |
WO2023212586A1 (en) | 2022-04-27 | 2023-11-02 | Regeneron Pharmaceuticals, Inc. | Methods for selecting patients for treatment with an ngf antagonist |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993006213A1 (en) * | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
WO2001027160A1 (en) * | 1999-10-14 | 2001-04-19 | Applied Molecular Evolution, Inc. | Methods of optimizing antibody variable region binding affinity |
Family Cites Families (174)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4013556A (en) * | 1976-08-19 | 1977-03-22 | Uop Inc. | Combination flow distribution and collection apparatus |
FR2413974A1 (en) | 1978-01-06 | 1979-08-03 | David Bernard | DRYER FOR SCREEN-PRINTED SHEETS |
SU975016A1 (en) * | 1979-12-17 | 1982-11-23 | Московский научно-исследовательский онкологический институт им.П.А.Герцена | Analgetic composition |
US4485045A (en) * | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4544045A (en) * | 1983-04-01 | 1985-10-01 | Allied Corporation | Mechanical actuator for a disc brake |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4574065A (en) * | 1983-12-21 | 1986-03-04 | Armstrong World Industries, Inc. | Non-directional floor tile |
US4663195A (en) * | 1984-08-15 | 1987-05-05 | Nordson Corporation | Continuous coating process for discrete articles |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4777127A (en) * | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US6548640B1 (en) * | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
JPH0826036B2 (en) | 1987-01-22 | 1996-03-13 | 協和醗酵工業株式会社 | Derivatives of physiologically active substance K-252 |
GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
AU3418389A (en) | 1988-03-28 | 1989-10-16 | Regents Of The University Of California, The | Nerve growth factor peptides |
US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
GB8823869D0 (en) * | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0454781B1 (en) | 1989-01-23 | 1998-12-16 | Chiron Corporation | Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof |
SE465573B (en) | 1989-03-14 | 1991-09-30 | Lope Medicine Ab | NERVOUS GROWTH FACTOR Peptides, ANTIBODY CORRESPONDING MATERIALS AND PROCEDURES FOR DETERMINING NATIVE NERVOUS GROWTH FACTORS |
US6673776B1 (en) | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
DE69032284T2 (en) | 1989-03-21 | 1998-10-08 | Vical Inc | EXPRESSION OF EXOGENOUS POLYNUCLEOTIDE SEQUENCES IN VERTEBLE |
ATE144793T1 (en) | 1989-06-29 | 1996-11-15 | Medarex Inc | BISPECIFIC REAGENTS FOR AIDS THERAPY |
EP1001032A3 (en) | 1989-08-18 | 2005-02-23 | Chiron Corporation | Recombinant retroviruses delivering vector constructs to target cells |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
ATE160288T1 (en) | 1989-08-28 | 1997-12-15 | Takeda Chemical Industries Ltd | ANTIBODIES, THEIR PRODUCTION AND USE |
JPH03163095A (en) | 1989-08-28 | 1991-07-15 | Takeda Chem Ind Ltd | Partial peptide of human nerve growth factor, antibody and use thereof |
US5656435A (en) * | 1989-08-28 | 1997-08-12 | Takeda Chemical Industries, Ltd. | Antibodies to peptides having NGF-like activity, said antibodies having no substantial cross-reactivity with NGF, and use thereof |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
FR2654332B1 (en) * | 1989-11-13 | 1997-11-21 | Biotrol Sa Lab | APPARATUS FOR STOMA. |
NZ237464A (en) | 1990-03-21 | 1995-02-24 | Depotech Corp | Liposomes with at least two separate chambers encapsulating two separate biologically active substances |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
KR100272077B1 (en) * | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) * | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) * | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
JPH06317587A (en) | 1990-08-31 | 1994-11-15 | Takeda Chem Ind Ltd | Antibody and its use |
US5147294A (en) * | 1990-10-01 | 1992-09-15 | Trustees Of Boston University | Therapeutic method for reducing chronic pain in a living subject |
EP0485927A1 (en) * | 1990-11-16 | 1992-05-20 | Hoechst Aktiengesellschaft | Sulfimidoperoxycarboxylic acids |
FR2669336B1 (en) * | 1990-11-20 | 1993-01-22 | Adir | NOVEL OXAZOLO PYRIDINES DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
US5278299A (en) | 1991-03-18 | 1994-01-11 | Scripps Clinic And Research Foundation | Method and composition for synthesizing sialylated glycosyl compounds |
WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
DE69233482T2 (en) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
DE69233254T2 (en) | 1991-06-14 | 2004-09-16 | Genentech, Inc., South San Francisco | Humanized Heregulin antibody |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
JP3534749B2 (en) | 1991-08-20 | 2004-06-07 | アメリカ合衆国 | Adenovirus-mediated gene transfer into the gastrointestinal tract |
US5210671A (en) * | 1991-08-29 | 1993-05-11 | Verbatim Corporation | Write protection for memory diskettes |
AU669124B2 (en) | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
JPH0576384A (en) | 1991-09-20 | 1993-03-30 | Hitachi Ltd | Anti-human nerve growth factor monoclonal antibody |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
AU3144193A (en) | 1991-11-21 | 1993-06-15 | Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
FR2688514A1 (en) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5180370A (en) * | 1992-05-18 | 1993-01-19 | Gillespie Elgene R | Safety hypodermic syringe with retractable needle |
WO1993025234A1 (en) | 1992-06-08 | 1993-12-23 | The Regents Of The University Of California | Methods and compositions for targeting specific tissue |
US5342942A (en) * | 1992-06-09 | 1994-08-30 | Warner-Lambert Company | Pyrazoloquinazolone derivatives as neurotrophic agents |
EP0644946A4 (en) | 1992-06-10 | 1997-03-12 | Us Health | Vector particles resistant to inactivation by human serum. |
GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
CA2140280A1 (en) | 1992-08-17 | 1994-03-03 | Avi J. Ashkenazi | Bispecific immunoadhesins |
US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
EP0911413A3 (en) | 1992-12-03 | 2000-11-15 | Genzyme Corporation | Minimal adenovirus-based gene therapy vector |
US5604260A (en) * | 1992-12-11 | 1997-02-18 | Merck Frosst Canada Inc. | 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 |
US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5409944A (en) * | 1993-03-12 | 1995-04-25 | Merck Frosst Canada, Inc. | Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase |
JP3545403B2 (en) | 1993-04-22 | 2004-07-21 | スカイファルマ インコーポレイテッド | Cyclodextrin liposomes encapsulating pharmaceutical compounds and methods of use |
IT1264456B1 (en) * | 1993-05-14 | 1996-09-23 | Dompe Farmaceutici Spa | DERIVATIVES OF PHARMACOLOGICALLY ACTIVE 2- (BENZIMIDAZOL-2-IL) -1,3-DIAMINOPROPANE. |
US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
US5436265A (en) * | 1993-11-12 | 1995-07-25 | Merck Frosst Canada, Inc. | 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents |
US5474995A (en) * | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
ATE304604T1 (en) | 1993-06-24 | 2005-09-15 | Frank L Graham | ADENOVIRUS VECTORS FOR GENE THERAPY |
DK0814154T3 (en) | 1993-09-15 | 2009-08-31 | Novartis Vaccines & Diagnostic | Recombinant alphavirus vectors |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
DE69435223D1 (en) | 1993-10-25 | 2009-09-03 | Canji Inc | Recombinant adenovirus vector and method of use |
RO116341B1 (en) | 1993-11-16 | 2001-01-30 | Depotech Corp La Jolia | Multivesicle liposome and process for producing the same |
CA2175893C (en) * | 1993-11-23 | 2010-06-22 | Paul J. Godowski | Protein tyrosine kinases named rse |
DE69408541T2 (en) | 1993-11-23 | 1998-08-06 | Genentech Inc | KINAS RECEPTOR ACTIVATION TEST |
GB9402331D0 (en) * | 1994-02-07 | 1994-03-30 | Univ Mcgill | Nerve growth factor structural analogs and their uses |
US5844092A (en) | 1994-03-18 | 1998-12-01 | Genentech, Inc. | Human TRK receptors and neurotrophic factor inhibitors |
US5877016A (en) | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
US6436908B1 (en) | 1995-05-30 | 2002-08-20 | Duke University | Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function |
ATE381624T1 (en) | 1994-05-09 | 2008-01-15 | Oxford Biomedica Ltd | RETROVIRAL VECTORS WITH REDUCED RECOMBINATION RATE |
US6291247B1 (en) * | 1994-05-11 | 2001-09-18 | Queen's University At Kingston | Methods of screening for factors that disrupt neurotrophin conformation and reduce neurotrophin biological activity |
US5475995A (en) | 1994-05-16 | 1995-12-19 | Livingston; George G. | Truck spare tire locking rod |
GB9514160D0 (en) | 1994-07-25 | 1995-09-13 | Zeneca Ltd | Aromatic compounds |
US5616601A (en) * | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
US5521213A (en) * | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
US5593994A (en) * | 1994-09-29 | 1997-01-14 | The Dupont Merck Pharmaceutical Company | Prostaglandin synthase inhibitors |
WO1996017072A2 (en) | 1994-11-30 | 1996-06-06 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
US5552422A (en) * | 1995-01-11 | 1996-09-03 | Merck Frosst Canada, Inc. | Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents |
US5604253A (en) * | 1995-05-22 | 1997-02-18 | Merck Frosst Canada, Inc. | N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors |
US5639780A (en) * | 1995-05-22 | 1997-06-17 | Merck Frosst Canada, Inc. | N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors |
US5510368A (en) * | 1995-05-22 | 1996-04-23 | Merck Frosst Canada, Inc. | N-benzyl-3-indoleacetic acids as antiinflammatory drugs |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
WO1997015593A1 (en) | 1995-10-25 | 1997-05-01 | Queen's University At Kingston | Neurotrophin antagonists |
GB9525180D0 (en) | 1995-12-08 | 1996-02-07 | Univ Mcgill | Design of hormone-like antibodies with agonistic and antagonistic fuctions |
AU2998597A (en) | 1996-05-06 | 1997-11-26 | Chiron Corporation | Crossless retroviral vectors |
UA67725C2 (en) * | 1996-06-03 | 2004-07-15 | Cephalon Inc | K-252a derivatives and a method for improvement of functioning and cell survival enhancement |
GB9616105D0 (en) | 1996-07-31 | 1996-09-11 | Univ Kingston | TrkA binding site of NGF |
DK0930883T3 (en) | 1996-10-21 | 2006-05-22 | Nps Allelix Corp | Neurotrophin antagonists for the treatment of epilepsy, Alzheimer's disease and pain |
US6284794B1 (en) * | 1996-11-05 | 2001-09-04 | Head Explorer Aps | Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase |
EP1829539A3 (en) | 1996-11-05 | 2008-02-20 | HEADEXPLORER ApS | A method for treating tension-type headache |
KR100500919B1 (en) * | 1997-02-10 | 2005-07-14 | 마츠시타 덴끼 산교 가부시키가이샤 | Resin sealed semiconductor device and method for manufacturing the same |
FR2759720B1 (en) * | 1997-02-19 | 1999-04-30 | Degremont | PROCESS FOR PRODUCING A FILTER FLOOR FOR WATER TREATMENT |
DE19732928C2 (en) * | 1997-07-31 | 2000-05-18 | Gruenenthal Gmbh | Use of substituted imidazolidine-2,4-dione compounds as pain relievers |
US5981650A (en) * | 1997-08-26 | 1999-11-09 | Ashland Inc. | Cold seal adhesives, cold sealable films and packages formed therewith |
US6376471B1 (en) | 1997-10-10 | 2002-04-23 | Johns Hopkins University | Gene delivery compositions and methods |
US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
GB9807781D0 (en) | 1998-04-09 | 1998-06-10 | Univ Bristol | Therapeutic agent |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
US6127401A (en) * | 1998-06-05 | 2000-10-03 | Cephalon, Inc. | Bridged indenopyrrolocarbazoles |
US6652864B1 (en) | 1998-12-21 | 2003-11-25 | Asilomar Pharmaceuticals, Inc. | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
CN1228995A (en) * | 1999-01-26 | 1999-09-22 | 卢杲 | Medicine for treating senils dementia, parkinsonism and cardio-cerebral angiopathy |
EP1158997A2 (en) | 1999-03-09 | 2001-12-05 | University Of Southern California | Method of promoting myocyte proliferation and myocardial tissue repair |
US6492380B1 (en) | 1999-05-17 | 2002-12-10 | Queen's University At Kingston | Method of inhibiting neurotrophin-receptor binding |
US6468990B1 (en) | 1999-05-17 | 2002-10-22 | Queen's University At Kingston | Method of inhibiting binding of nerve growth factor to p75 NTR receptor |
IT1306704B1 (en) | 1999-05-26 | 2001-10-02 | Sirs Societa Italiana Per La R | MONOCLONAL ANTIBODIES AND ITS SYNTHETIC OR BIOTECHNOLOGICAL DERIVATIVES ENABLE TO ACT AS ANTAGONIST MOLECULES FOR NGF. |
US6399780B1 (en) * | 1999-08-20 | 2002-06-04 | Cephalon, Inc. | Isomeric fused pyrrolocarbazoles and isoindolones |
AU1086501A (en) | 1999-10-15 | 2001-04-30 | Carnegie Institution Of Washington | Rna interference pathway genes as tools for targeted genetic interference |
DK1265605T3 (en) | 2000-01-18 | 2007-02-12 | Univ Mcgill | Pharmaceutical compositions comprising peptide mimetic cyclic beta rotation compound |
US6548062B2 (en) * | 2000-02-29 | 2003-04-15 | Cephalon, Inc. | Method of treating cancer with anti-neurotrophin agents |
FR2807660A1 (en) * | 2000-04-13 | 2001-10-19 | Warner Lambert Co | Use of a nerve growth factor antagonist for the manufacture of a medicament for the prevention or treatment of chronic visceral pain |
ATE513910T1 (en) | 2000-05-30 | 2011-07-15 | Johnson & Johnson Res Pty Ltd | METHODS OF GENE SUPPRESSION USING RNAI ENHANCEMENT FACTORS |
US7022484B2 (en) * | 2000-06-08 | 2006-04-04 | Board Of Regents, The University Of Texas System | Methods for treating neuropathological states and neurogenic inflammatory states and methods for identifying compounds useful therein |
GB0020504D0 (en) | 2000-08-18 | 2000-10-11 | Univ Bristol | Therapeutic method |
US6630500B2 (en) | 2000-08-25 | 2003-10-07 | Cephalon, Inc. | Selected fused pyrrolocarbazoles |
AU2001288374A1 (en) | 2000-09-01 | 2002-03-22 | Glaxo Group Limited | Substituted oxindole derivatives as tyrosine kinase inhibitors |
WO2002020513A1 (en) | 2000-09-01 | 2002-03-14 | Glaxo Group Limited | Oxindole derivatives |
US20040259247A1 (en) | 2000-12-01 | 2004-12-23 | Thomas Tuschl | Rna interference mediating small rna molecules |
KR20040049829A (en) | 2001-05-30 | 2004-06-12 | 제넨테크, 인크. | Anti-ngf antibodies for the treatment of various disorders |
AU2002310441A1 (en) | 2001-06-14 | 2003-01-02 | The Regents Of The University Of California | A novel signaling pathway for the production of inflammatory pain and neuropathy |
EP1434576A4 (en) | 2001-09-13 | 2006-03-29 | Kenneth E Miller | Method of alleviating pain |
CN1678634A (en) * | 2002-06-28 | 2005-10-05 | 多曼蒂斯有限公司 | Immunoglobulin single variable antigen combination area and its opposite constituent |
US20040038874A1 (en) * | 2002-08-22 | 2004-02-26 | Osemwota Omoigui | Method of treatment of persistent pain |
AU2003294221A1 (en) | 2002-09-13 | 2004-04-19 | Kenneth E. Miller | Method of alleviating pain via inhibition of neurotransmitter synthesis |
US6919426B2 (en) * | 2002-09-19 | 2005-07-19 | Amgen Inc. | Peptides and related molecules that modulate nerve growth factor activity |
US20060147450A1 (en) | 2002-10-04 | 2006-07-06 | Shelton David L | Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists |
UA80447C2 (en) * | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
RU2338555C2 (en) | 2002-10-08 | 2008-11-20 | Ринат Ньюросайенс Корп. | Method of treatment of postoperative pain by administering of antagonist of factor of growth of nerves and compositions containing factor of growth of nerves |
AU2003304238A1 (en) | 2002-10-08 | 2005-01-13 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same |
JP3818255B2 (en) | 2002-12-16 | 2006-09-06 | 住友電気工業株式会社 | Optical fiber having diffractive optical film at end and manufacturing method thereof |
US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
US9498530B2 (en) * | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
SI1575517T1 (en) | 2002-12-24 | 2012-06-29 | Rinat Neuroscience Corp | Anti-ngf antibodies and methods using same |
US20060147932A1 (en) | 2003-01-18 | 2006-07-06 | Alun Davies | Methods of screening for modulators of nerve growth factor |
PL379983A1 (en) | 2003-02-19 | 2006-11-27 | Rinat Neuroscience Corp. | Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same |
JP3923028B2 (en) | 2003-04-28 | 2007-05-30 | シャープ株式会社 | Image recording system and image recording apparatus |
NZ544751A (en) | 2003-07-15 | 2009-05-31 | Amgen Inc | Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors |
JP5301152B2 (en) | 2004-04-07 | 2013-09-25 | ライナット ニューロサイエンス コーポレイション | Method for treating bone cancer pain by administering a nerve growth factor antagonist |
CA2595800C (en) | 2005-01-24 | 2014-07-08 | Cambridge Antibody Technology Limited. | Specific binding members for ngf |
KR101709488B1 (en) * | 2007-08-10 | 2017-02-24 | 리제너론 파아마슈티컬스, 인크. | High affinity human antibodies to human nerve growth factor |
BRPI0917888A2 (en) | 2008-09-19 | 2014-02-25 | Pfizer | STABLE NET ANTIBODY FORMULATION |
TWI486171B (en) | 2009-05-04 | 2015-06-01 | 亞培研究公司 | Antibodies against nerve growth factor (ngf) with enhanced in vivo stability |
US9505829B2 (en) * | 2010-08-19 | 2016-11-29 | Zoetis Belgium S.A. | Anti-NGF antibodies and their use |
US9783601B2 (en) * | 2010-12-01 | 2017-10-10 | Alderbio Holdings Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
GB201114858D0 (en) | 2011-08-29 | 2011-10-12 | Nvip Pty Ltd | Anti-nerve growth factor antibodies and methods of using the same |
JP6629069B2 (en) * | 2012-06-06 | 2020-01-15 | ゾエティス・エルエルシー | Canine anti-NGF antibody and method thereof |
-
2003
- 2003-12-24 SI SI200332143T patent/SI1575517T1/en unknown
- 2003-12-24 EP EP18195127.8A patent/EP3539569A1/en not_active Withdrawn
- 2003-12-24 CA CA2511598A patent/CA2511598C/en not_active Expired - Fee Related
- 2003-12-24 CA CA2936742A patent/CA2936742C/en not_active Expired - Fee Related
- 2003-12-24 PT PT10176615T patent/PT2263692T/en unknown
- 2003-12-24 EP EP10176627.7A patent/EP2270048B1/en not_active Expired - Lifetime
- 2003-12-24 CN CN201110411417.3A patent/CN102746399B/en not_active Expired - Lifetime
- 2003-12-24 PT PT03800170T patent/PT1575517E/en unknown
- 2003-12-24 ZA ZA200504866A patent/ZA200504866B/en unknown
- 2003-12-24 PT PT101766277T patent/PT2270048E/en unknown
- 2003-12-24 EA EA200501043A patent/EA011479B1/en unknown
- 2003-12-24 EP EP10176615.2A patent/EP2263692B1/en not_active Expired - Lifetime
- 2003-12-24 ES ES10176615T patent/ES2697876T3/en not_active Expired - Lifetime
- 2003-12-24 DK DK03800170.7T patent/DK1575517T3/en active
- 2003-12-24 AU AU2003299898A patent/AU2003299898B2/en not_active Expired
- 2003-12-24 CA CA2921578A patent/CA2921578C/en not_active Expired - Fee Related
- 2003-12-24 NZ NZ540730A patent/NZ540730A/en not_active IP Right Cessation
- 2003-12-24 ES ES03800170T patent/ES2382918T3/en not_active Expired - Lifetime
- 2003-12-24 HU HUE10176627A patent/HUE026089T2/en unknown
- 2003-12-24 CN CN2003801099334A patent/CN101014364B/en not_active Expired - Lifetime
- 2003-12-24 KR KR1020057011944A patent/KR101250818B1/en active IP Right Grant
- 2003-12-24 JP JP2005510064A patent/JP4134170B2/en not_active Expired - Fee Related
- 2003-12-24 PL PL380679A patent/PL215171B1/en unknown
- 2003-12-24 EP EP03800170A patent/EP1575517B1/en not_active Expired - Lifetime
- 2003-12-24 NZ NZ587852A patent/NZ587852A/en not_active IP Right Cessation
- 2003-12-24 KR KR1020127025397A patent/KR101410692B1/en active IP Right Grant
- 2003-12-24 WO PCT/US2003/041252 patent/WO2004058184A2/en active Application Filing
- 2003-12-24 AT AT03800170T patent/ATE553128T1/en active
- 2003-12-24 BR BRPI0317738A patent/BRPI0317738B8/en active IP Right Grant
- 2003-12-24 DK DK10176627.7T patent/DK2270048T3/en active
- 2003-12-24 SI SI200332455T patent/SI2270048T1/en unknown
- 2003-12-24 US US10/745,775 patent/US7449616B2/en active Active
- 2003-12-24 MX MXPA05006854A patent/MXPA05006854A/en not_active Application Discontinuation
- 2003-12-24 SI SI200332584T patent/SI2263692T1/en unknown
- 2003-12-24 ES ES10176627.7T patent/ES2564752T3/en not_active Expired - Lifetime
- 2003-12-24 DK DK10176615.2T patent/DK2263692T3/en active
-
2005
- 2005-06-16 IL IL169221A patent/IL169221A/en active IP Right Grant
- 2005-07-22 NO NO20053583A patent/NO336655B1/en not_active IP Right Cessation
- 2005-11-23 HK HK05110620.2A patent/HK1076251A1/en not_active IP Right Cessation
-
2007
- 2007-01-12 US US11/653,206 patent/US7655232B2/en not_active Expired - Lifetime
-
2008
- 2008-01-16 JP JP2008007312A patent/JP4336728B2/en not_active Expired - Fee Related
- 2008-02-05 HK HK08101386.2A patent/HK1110513A1/en not_active IP Right Cessation
-
2009
- 2009-03-03 JP JP2009049629A patent/JP2009159977A/en active Pending
- 2009-11-16 US US12/618,896 patent/US8088384B2/en active Active
-
2011
- 2011-11-22 US US13/302,264 patent/US9212222B2/en active Active
-
2012
- 2012-02-13 IL IL218087A patent/IL218087B/en active IP Right Grant
-
2013
- 2013-04-23 HK HK13104894.4A patent/HK1177754A1/en not_active IP Right Cessation
-
2015
- 2015-04-20 NO NO20150469A patent/NO339595B1/en not_active IP Right Cessation
- 2015-11-13 US US14/940,710 patent/US9708398B2/en not_active Expired - Lifetime
-
2017
- 2017-06-14 US US15/622,551 patent/US11008386B2/en not_active Expired - Lifetime
-
2018
- 2018-12-09 IL IL263573A patent/IL263573A/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993006213A1 (en) * | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
WO2001027160A1 (en) * | 1999-10-14 | 2001-04-19 | Applied Molecular Evolution, Inc. | Methods of optimizing antibody variable region binding affinity |
Non-Patent Citations (2)
Title |
---|
ALOE ET AL.: "The synovium of transgenic arthritic mice expressing human tumor necrosis factorcontains a high level of nerve growth factor", GROWTH FACTORS, vol. 9, no. 2, 1993, pages 149 - 155, XP008070582 * |
HONGO ET AL.: "ANTIBODY BINDING REGIONS ON HUMAN NERVE GROWTH FACTOR IDENTIFIED BY HOMOLOG- ANDALANINE-SCANNING MUTAGENESIS", HYBRIDOMA, vol. 19, 2000, pages 215 - 277, XP002951932 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8030469B2 (en) | 2005-07-22 | 2011-10-04 | Sbi Incubation Co., Ltd. | Anti-CD26 antibodies and methods of use thereof |
US8435523B2 (en) | 2009-05-04 | 2013-05-07 | Abbott Research B.V. | Antibodies against nerve growth factor (NGF) with enhanced in vivo stability |
US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL263573A (en) | Anti-ngf antibodies and methods using same | |
WO2006110883A3 (en) | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same | |
WO2006060513A3 (en) | Toll like receptor 3 antagonists, methods and uses | |
EP1635871A4 (en) | Methods and compositions for treating rheumatoid arthritis | |
WO2005000194A3 (en) | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same | |
WO2007120656A3 (en) | Uses and compositions for treatment of rheumatoid arthritis | |
WO2004081021A3 (en) | Oligonucleotide mimetics | |
WO2001064889A3 (en) | Tnf-alpha variants for the treatment of tnf-alpha related disorders | |
WO2007120651A3 (en) | Uses and compositions for treatment of juvenile rheumatoid arthritis | |
WO2003084560A3 (en) | Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis | |
ZA200205191B (en) | LIV-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer. | |
WO2005023201A3 (en) | Methods for treating rheumatoid arthritis | |
WO2004043379A3 (en) | Chemical compounds | |
IL174242A0 (en) | Treatment of rheumatoid arthritis with cd99 antagonists | |
WO2003070904A3 (en) | Human rnase iii and compositions and uses thereof | |
AU2002368150A1 (en) | Use of methylnaltrexone in treating gastrointestinal dysfunction in equines | |
WO2002002630A3 (en) | Hcn polypeptides and polynucleotides and their use in therapy | |
WO2005062955A3 (en) | Agonist anti-trkc antibodies and methods using same | |
EP1578368A4 (en) | Compositions and methods for the treatment of rheumatoid arthritis | |
AU2003266960A1 (en) | Composition for the treatment of pain, especially for the treatment of articular pain | |
AU2003259028A8 (en) | Combinations for the treatment of rheumatoid arthritis | |
WO2005041862A3 (en) | Neutralizing antibodies against extracellular hexosaminidase for treatment of arthritis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 540730 Country of ref document: NZ Ref document number: 200504866 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 169221 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003800170 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003299898 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/006854 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2511598 Country of ref document: CA Ref document number: 2005510064 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057011944 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 05071385 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200501043 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038A99334 Country of ref document: CN |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWP | Wipo information: published in national office |
Ref document number: 2003800170 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057011944 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: PI0317738 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 218087 Country of ref document: IL |